1-16 of 16
Amy M. Lehman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Genome-Wide CRISPR/Cas9 Knockout Screen Reveals Novel Gilteritinib Combinations Targeting Oxidative Phosphorylation and De-Novo Purine Biosynthesis Pathways for FLT3-ITD + Acute Myeloid Leukemia

Steven Sher, Pu Zhang, Lindsey Brinton, Mehdi Gharghabi, Katie Williams, Matthew Cannon, Janek S. Walker, Daniel Canfield, Larry Beaver, Casey B. Cempre, Hannah Phillips, Xuyong Chen, Pearlly S. Yan, Amy M. Lehman, Peggy Scherle, Min Wang, Kris Vaddi, Robert A. Baiocchi, Ruoning Wang, Deepa Sampath, Lapo Alinari, James S. Blachly, Rosa Lapalombella
Journal: Blood
Blood (2022) 140 (Supplement 1): 681–682.
https://doi.org/10.1182/blood-2022-165573
Published: 2022
Journal Articles

The Protein Kinase C Inhibitor MS-553 for the Treatment of Chronic Lymphocytic Leukemia

Elizabeth M. Muhowski, Amy M. Lehman, M.A.S, Sean D. Reiff, PhD, Janani Ravikrishnan, Rose Mantel, Shrilekha Misra, Michael Niesman, PhD, Kai Zhang, MD, James S. Blachly, MD, Deepa Sampath, PhD, John C. Byrd, MD, Jennifer Woyach, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2077.
https://doi.org/10.1182/blood-2019-128871
Published: 2019
Journal Articles

NAMPT Inhibitor KPT-9274 Selectively Targets Self-Renewal Capacity in Acute Myeloid Leukemia

Shaneice Renee Mitchell, BS, Nicole Grieselhuber, MD PhD, Yerdanos Asemelash, Matthew Cannon, BA, Shelley Orwick, BS, Pratibha Sharma, PhD, Virginia Goettl, DVM, PhD, Vinay K Puduvalli, MD MBBS, Deepa Sampath, PhD, Alice S. Mims, MD, James S. Blachly, MD, Amy M. Lehman, PhD, Bonnie K. Harrington, DVM, Justin Breitbach, Erkan Baloglu, William Senapedis, PhD, Rosa Lapalombella, PhD, John C. Byrd, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3931.
https://doi.org/10.1182/blood-2018-99-119358
Published: 2018
Journal Articles

PRMT5 Initiates an Epigenetic Program That Promotes Progression of Chronic Lymphocytic Leukemia

Zachary A Hing, BS, Jordan N. Skinner, B.S., Larry P. Beaver, Tzung-Huei Lai, PhD, Casey B. Cempre, B.S., Bonnie K. Harrington, DVM, Deepa Sampath, PhD, Amy M. Lehman, PhD, Lianbo Yu, PhD, Lapo Alinari, MD PhD, John C. Byrd, MD, Robert A Baiocchi, MD PhD, Rosa Lapalombella, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2487.
https://doi.org/10.1182/blood.V130.Suppl_1.2487.2487
Published: 2017
Journal Articles

NF-κB p50 ( nfkb1 ) contributes to pathogenesis in the Eμ-TCL1 mouse model of chronic lymphocytic leukemia

Timothy L. Chen, Minh Tran, Aparna Lakshmanan, Bonnie K. Harrington, Nikhil Gupta, Virginia M. Goettl, Amy M. Lehman, Stephen Trudeau, David M. Lucas, Amy J. Johnson, John C. Byrd, Erin Hertlein
Journal: Blood
Blood (2017) 130 (3): 376–379.
https://doi.org/10.1182/blood-2017-01-761130
Published: 2017
Includes: Supplemental data
Journal Articles

BRAF V600E Accelerates Disease Progression and Increases Immune Suppression in a Mouse Model of B-Cell Leukemia

Yo-Ting Tsai, MS, Aparna Lakshmanan, PhD, Amy M. Lehman, MAS, Ellen J. Sass, Minh Tran, Fabienne McClanahan, MD PhD, Meixiao Long, MD PhD, Bonnie K. Harrington, DVM, Krista La Perle, DVM, PhD, Vincenzo Coppola, MD, Gerard Lozanski, MD, Natarajan Muthusamy, DVM, PhD, John C. Byrd, MD, Michael R. Grever, MD, David M. Lucas, PhD
Journal: Blood
Blood (2016) 128 (22): 1206.
https://doi.org/10.1182/blood.V128.22.1206.1206
Published: 2016
Journal Articles

Inhibitors of Bruton's Tyrosine Kinase Reduce Anti-Red Blood Cell Response in a Murine Model of Autoimmune Hemolytic Anemia

Kerry A. Rogers, MD, Amy M. Lehman, MAS, Carolyn Cheney, BS, Virginia M. Goettl, DVM , PhD, Rose Mantel, Lisa L. Smith, MS, Minh Tran, Amy J. Johnson, PhD, John C. Byrd, MD, Jennifer A. Woyach, MD
Journal: Blood
Blood (2016) 128 (22): 1259.
https://doi.org/10.1182/blood.V128.22.1259.1259
Published: 2016
Journal Articles

Ibrutinib Represents a Novel Class of Immune Modulating Therapeutics That Enhances the Survival of Activated T Cells in Vitro and In Vivo through a Non-BTK Mediated Mechanism

Meixiao Long, MD PhD, Kyle A. Beckwith, PhD, Priscilla Do, BS, Mundy L Bethany, PhD, Gordon Gordon, Amy M. Lehman, MAS, Kami J. Maddocks, MD, Carolyn Cheney, BS, Jeffrey Jones, MD MPH, Leslie A. Andritsos, MD, Farrukh T. Awan, Joseph A. Fraietta, PhD, Carl H June, MD, Marcela V. Maus, MDPhD, Jennifer A. Woyach, MD, Michael A. Caligiuri, MD, Amy J. Johnson, PhD, Natarajan Muthusamy, DVM, PhD, John C. Byrd, MD
Journal: Blood
Blood (2016) 128 (22): 3238.
https://doi.org/10.1182/blood.V128.22.3238.3238
Published: 2016
Journal Articles

Next Generation XPO1 Inhibitor Shows Improved Efficacy and In Vivo Tolerability in Hematologic Malignancies

Zachary A. Hing, BS, Ho Yee Joyce Fung, BA, Parvathi Ranganathan, PhD, Shaneice Mitchell, BS, Dalia El-Gamal, PhD, Jennifer A. Woyach, MD, Katie Williams, MS, Virginia M. Goettl, DVM, PhD, Jordan L. Smith, BS, Xueyan Yu, Xiaomei Meng, Qingxiang Sun, PhD, Tolga Cagatay, PhD, John B. MacMillan, PhD, Amy M. Lehman, MAS, David M. Lucas, PhD, Erkan Baloglu, PhD, Sharon Shacham, Michael Kauffman, MD PhD, John C. Byrd, MD, Yuh Min Chook, PhD, Ramiro Garzon, MD, Rosa Lapalombella, PhD
Journal: Blood
Blood (2015) 126 (23): 317.
https://doi.org/10.1182/blood.V126.23.317.317
Published: 2015
Journal Articles

A Novel Inhibitor of BET Family Bromodomains Demonstrates In Vivo and I n Vi tro Potency in B-Cell Malignancies

Dalia El-Gamal, PhD, Zachary A. Hing, BS, Shaneice Mitchell, BS, Taylor D. LaFollette, Paul J. Brennan, Joseph M. Flynn, DO, MPH, Jeffrey A. Jones, MD MPH, Farrukh Awan, MD MS, Leslie A. Andritsos, MD, James S. Blachly, MD, Katie Williams, MS, Bonnie K. Harrington, DVM, Virginia M. Goettl, DVM, PhD, Jennifer A. Woyach, MD, Amy M. Lehman, MAS, Lianbo Yu, PhD, John C. Byrd, MD, Rosa Lapalombella, PhD
Journal: Blood
Blood (2015) 126 (23): 318.
https://doi.org/10.1182/blood.V126.23.318.318
Published: 2015
Journal Articles

NFkB p50 ( Nfkb1 ) Contributes to Disease in the Eu-TCL1 Mouse Model of Chronic Lymphocytic Leukemia

Erin K Hertlein, PhD, Timothy L Chen, David M Lucas, PhD, Nikhil Gupta, Jessica MacMurray, Virginia M. Goettl, DVM , PhD, Amy M. Lehman, MAS, Amy J. Johnson, PhD, John C Byrd, MD
Journal: Blood
Blood (2015) 126 (23): 1248.
https://doi.org/10.1182/blood.V126.23.1248.1248
Published: 2015
Journal Articles

The Aberrantly Expressed Long Noncoding RNA, TRERNA1, Predicts for Aggressive Disease in Chronic Lymphocytic Leukemia

Cecelia R Miller, MS, Amy S. Ruppert, MAS, Kevin Coombes, PhD, Amy M. Lehman, MAS, James S. Blachly, MD, David M. Lucas, PhD, Michael R. Grever, MD, Martin S Tallman, MD, Ian W. Flinn, MD PhD, Laura Z. Rassenti, PhD, Thomas J. Kipps, MD PhD, Deepa Sampath, PhD, John C Byrd, MD, Erin K. Hertlein, PhD
Journal: Blood
Blood (2015) 126 (23): 2911.
https://doi.org/10.1182/blood.V126.23.2911.2911
Published: 2015
Journal Articles

BRAF V600E Induces ABCB1/P-Glycoprotein Expression and Drug Resistance in B-Cells Via AP-1 Activation

Yo-Ting Tsai, MS, Gerard Lozanski, MD, Amy M. Lehman, MAS, Ellen Sass, Erin K. Hertlein, PhD, Santosh Salunke, Ching-Shih Chen, PhD, Michael R. Grever, MD, John C. Byrd, MD, David M. Lucas, PhD
Journal: Blood
Blood (2015) 126 (23): 2477.
https://doi.org/10.1182/blood.V126.23.2477.2477
Published: 2015
Journal Articles

Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling

Yuh-Ying Yeh, Hatice Gulcin Ozer, Amy M. Lehman, Kami Maddocks, Lianbo Yu, Amy J. Johnson, John C. Byrd
Journal: Blood
Blood (2015) 125 (21): 3297–3305.
https://doi.org/10.1182/blood-2014-12-618470
Published: 2015
Includes: Supplemental data
Journal Articles

Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia

Brief Report
Zachary A. Hing, Rose Mantel, Kyle A. Beckwith, Daphne Guinn, Erich Williams, Lisa L. Smith, Katie Williams, Amy J. Johnson, Amy M. Lehman, John C. Byrd, Jennifer A. Woyach, Rosa Lapalombella
Journal: Blood
Blood (2015) 125 (20): 3128–3132.
https://doi.org/10.1182/blood-2015-01-621391
Published: 2015
Includes: Supplemental data
Journal Articles

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

Jason A. Dubovsky, Kyle A. Beckwith, Gayathri Natarajan, Jennifer A. Woyach, Samantha Jaglowski, Yiming Zhong, Joshua D. Hessler, Ta-Ming Liu, Betty Y. Chang, Karilyn M. Larkin, Matthew R. Stefanovski, Danielle L. Chappell, Frank W. Frissora, Lisa L. Smith, Kelly A. Smucker, Joseph M. Flynn, Jeffrey A. Jones, Leslie A. Andritsos, Kami Maddocks, Amy M. Lehman, Richard Furman, Jeff Sharman, Anjali Mishra, Michael A. Caligiuri, Abhay R. Satoskar, Joseph J. Buggy, Natarajan Muthusamy, Amy J. Johnson, John C. Byrd
Journal: Blood
Blood (2013) 122 (15): 2539–2549.
https://doi.org/10.1182/blood-2013-06-507947
Published: 2013
Includes: Supplemental data